This is to remind you that the deadline for the survey is tomorrow. Here are the results so far per country: Denmark 1 Estonia 1 France 2 Germany 4 Ireland 1 Slovenia 1 Spain 8 Sweden 6 Switzerland 7 the Netherlands 5 Turkey 4 We still have no response from many European countries, which lowers the value of our survey. Please get in touch with me if you know specific people who have not filled in the survey and can do so quickly. You'll find the names of the institutes who have answered below, Kind regards, Gabrielle Dept. Medical Sciences, Molecular Medicine national centre for medical genetics The EStonian Genome Center of University of Tartu Diagnostikcentrum, Clinical Pathology and Clinical Genetics University of Lausanne CHUV Uppsala University; SNP&SEQ Technology platform + Uppsala Genome Center University Hospital Copenhagen Institute of Medical Genetics at the University of Zurich Kantonsspital Olten Division of Human Genetics Leiden University Medical Center Center for Human Genetics and Laboratory Medicine Institut Central des Hopitaux Valaisans-RSV Humangenetics İstanbul University Institute of Experimental Medicine Max Planck Institute for Molecular Genetics UMC Utrecht Leiden University Medical Center TUBITAK, MAM, Genetic Engineering and Biotechnology Institute VUMC Lund University Diabetes Centre Science For Life Laboratory Department of Medical genetics & Inserm U 910 Helmholtz Zentrum Zentrum München Hôpital Timone Enfants et faculté de Médecine Center for Genomic Regulation INGEMM Fundacion Investigación Clínico de Valencia-INCLIVA Instituto de Salud Carlos III Uppsala University. Immunology, Genetics and Pathology / SciLifeLab Hospital Universitario Ramon y Cajal Hospital de Terrassa Complexo Hospitalario Universitario de Santiago Clinical institute of medical genetics Ljubljana Maastricht UMC+, Department of Clinical Genetics Sabanci University Institute of Medical Genetics and Applied Genomics, University of Tuebingen Hospital San Pedro de Alcántara TUBITAK-BILGEM From: Gabrielle Anne Bertier Sent: 28 September, 2012 18:12 PM To: &#39;geuvadis_partners(a)lists.crg.es&#39;.es'; &#39;geuvadis_exome(a)lists.crg.es&#39;.es'; &#39;geuvadis_wpl(a)lists.crg.es&#39;.es'; &#39;geuvadis_rnaseq(a)lists.crg.es&#39;.es'; &#39;geuvadis_rna_analysis(a)lists.crg.es&#39; Cc: Xavier Estivill; Michela Bertero; 'Bea Sobrino' Subject: IMPORTANT NOTICE: GEUVADIS survey DEADLINE EXTENDED Dear all, I remind you that we would highly appreciate if you could fill in, and distribute our survey on NGS to all your relevant colleagues. Note that we've extended the deadline to the 10th October 2012 Full survey link: https://qtrial.qualtrics.com/SE/?SID=SV_bHJDue550PwdFrv To describe the survey please use freely the following text: ------------------ THE GEUVADIS PROJECT - More information on our website: www.geuvadis.eu<file:///C:\Users\gbertier\Documents\GEUVADIS\Annual%20Me… The latest high-throughput next-generation sequencing technologies allow investigators to sequence entire human genomes and transcriptomes at an affordable price and within a short time frame. An increasing number of research centers in Europe have access to these technologies, in-house or through regional, national and international infrastructures. Storing, disseminating and analysing the large amount of data produced generate major challenges. Tackling these challenges requires extensive exchange of data, information and knowledge between sequencing centers, bio-informatics networks, the medical research community and the industry at the European level. The GEUVADIS (Genetic EUropean VAriation in DISease) Consortium has four main aims: 1. Develop standards in quality control and assessment of sequence data 2. Develop models for sequencing data storage, access and exchange 3. Develop standards for the handling, analysis and interpretation of sequencing data from DNA (and RNA) 4. Develop guidelines on the handling of ethical, legal and social implications of phenotype prediction from sequence variation * PURPOSE OF SURVEY 1. Collect quantitative and qualitative information on the current status of DNA sequence production, storage, exchange and analysis in Europe. 2. Collect feedback from research/clinical centers on their main challenges and difficulties regarding the management of these large data-sets potentially containing important medical information 3. Collect information on local standardization efforts, and avoid duplication of efforts throughout Europe 4. Create a road-map/policy document outlining the necessary steps to take national standards to the European level * POTENTIAL PUBLICATION OF RESULTS 1. Results of this survey will be presented at an internal GEUVADIS workshop, on October 30-31st 2012. 2. We will disseminate the road-map to potential funders (private of public), including the European Commission and other possible national public funders. 3. We will submit an abstract to the Joint Conference of Human Genome Meeting 2013 and 21st International Congress of Genetics. * DEADLINE: 30.09.2012 --------------------- If you have any question or comment regarding the Annual Meeting, the workshop and/or the survey please don't hesitate to contact me. Kind regards, Gabrielle.- Gabrielle Bertier Scientific Project Manager International and Scientific Affairs CRG, Center for Genomic Regulation Carrer Dr. Aiguader, 88 08003 Barcelona, España Tel: +34933160374 Mobile: +34639960656 email: gabrielle.bertier@crg.es<mailto:gabrielle.bertier@crg.es> web: www.geuvadis.eu; www.fliact.eu